Type II cGMP-dependent protein kinase inhibits epidermal growth factor-induced phosphatidylinositol-3-kinase/Akt signal transduction in gastric cancer cells

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1723-1728

  Wu, Min ^a   Chen, Yongchang ^a   Jiang, Lu ^a   Li, Yueying ^a   Lan, Ting ^a   Wang, Ying ^a   Qian, Hai ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Apoptosis; Gastric cancer cells; Phosphatidylinositol 3 kinase Akt mediated signal transduction; Type II cGMP dependent protein kinase

Indexed keywords

CASPASE 9; CYCLIC GMP DEPENDENT PROTEIN KINASE 2; EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; NICK END LABELING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

EID: 84886801328     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1630     Document Type: Article

References (27)

1. Marone R, Cmiljanovic V, Giese B and Wymann MP: Targeting phosphoinositide 3-kinase: moving towards therapy. Biochem Biophys Acta 1784: 159-185, 2008.
2. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
3. Edward LA, Thiesen B, Dragowska WH, et al: Inhibiton of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis and delays tumor growth. Oncogene 24: 3596-3605, 2005.
4. Berg M and Soreide K: EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 14: 207-214, 2012.
5. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: its functions and alteration in human cancer. Apoptosis 9: 667-676, 2004.
6. Orstavik S, Natarajan V, Taskén K, et al: Characterization of the human gene encoding the type I alpha and type I beta cGMP-dependent protein kinase (PRKG1). Genomics 42: 311-318, 1997.
7. Orstavik S, Solberg R, Taskén K, et al: Molecular cloning, cDNA structure and chromosomal localization of the human type II cGMP-dependent protein kinase. Biochem Biophys Res Commun 220: 759-765, 1996.
8. Browing DD: Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer. Expert Opin Ther Targets 12: 367-376, 2008.
9. Yang SQ, Chen YC, Wang Y, et al: Expression of cGMP dependent protein kinase II in cancer cell lines was obviously decreased. J Jiangsu Univ (Medicine Edition) 18: 1-5, 2008.
10. Chen YC, Ren F, Sang JR, et al: Type II cGMP-dependent protein kinase inhibits proliferation of the gastric cancer cell line BGC-823. Mol Med Rep 3: 361-366, 2010.
11. Wu Y, Chen Y, Qu R, et al: Type II cGMP-dependent protein kinase inhibits EGF-triggered signal transduction of the MAPK/ERK-mediated pathway in gastric cancer cells. Oncol Rep 27: 553-558, 2012.
12. Lan T, Chen Y, Sang J, et al: Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast cancer cells. Oncol Rep 27: 2039-2044, 2012.
13. Dong P, Xu Z, Jia N, et al: Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer 8: 103, 2009.
14. Quesnelle KM, Boehm AL and Grandis JR: STAT-mediated EGFR signaling in cancer. J Cell Biochem 102: 311-319, 2007.
15. Hofmann F: The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280: 1-4, 2005.
16. Nie HG, Chen L, Han DY, et al: Regulation of epithelial sodium channels by cGMP/PKGII. J Physiol 587: 2663-2676, 2009.
17. Rangaswami H, Marathe N, Zhuang S, et al: Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction. J Biol Chem 284: 14796-14808, 2009.
18. Rangaswami H, Schwappacher R, Marathe N, et al: Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblasts. Sci Signal 3: ra91, 2010.
19. Cook AL and Haynes JM: Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16: 253-261, 2004.
20. Swartling FJ, Ferletta M, Kastemar M, et al: Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene 28: 3121-3131, 2009.
21. Fallahian F, Karami-Tehrani F, Salami S and Aghaei M: Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and-negative breast cancer cell lines. FEBS J 278: 3360-3369, 2011.
22. Xie Z, Peng J, Pennypacker SD and Chen Y: Critical role for the catalytic activity of phospholipase C-γ1 in epidermal growth factor-induced cell migration. Biochem Biophys Res Commun 399: 425-428, 2010.
23. Yap TA, Garrett MD, Walton MI, et al: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412, 2008.
24. Normanno N, Bianco C, De Luca A, et al: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21, 2003.
25. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
26. Hynes NE and MacDonald G: ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184, 2009.
27. Quatrale AE, Porcelli L, Silvestris N, et al: EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci 16: 1962-1972, 2011.